These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 15533448)

  • 1. Nucleic acid and prion protein interaction produces spherical amyloids which can function in vivo as coats of spongiform encephalopathy agent.
    Nandi PK; Nicole JC
    J Mol Biol; 2004 Nov; 344(3):827-37. PubMed ID: 15533448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 25 nm virion is the likely cause of transmissible spongiform encephalopathies.
    Manuelidis L
    J Cell Biochem; 2007 Mar; 100(4):897-915. PubMed ID: 17044041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intriguing nucleic-acid-binding features of mammalian prion protein.
    Silva JL; Lima LM; Foguel D; Cordeiro Y
    Trends Biochem Sci; 2008 Mar; 33(3):132-40. PubMed ID: 18243708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Experimental approaches to the interaction of the prion protein with nucleic acids and glycosaminoglycans: Modulators of the pathogenic conversion.
    Silva JL; Vieira TC; Gomes MP; Rangel LP; Scapin SM; Cordeiro Y
    Methods; 2011 Mar; 53(3):306-17. PubMed ID: 21145399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of infective property of recombinant prion protein amyloids in cultured cells overexpressing cellular prion protein.
    Kim DH; Lee HM; Ryou C
    J Korean Med Sci; 2014 Dec; 29(12):1604-9. PubMed ID: 25469058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prions and transmissible spongiform encephalopathy (TSE) chemotherapeutics: A common mechanism for anti-TSE compounds?
    Caughey B; Caughey WS; Kocisko DA; Lee KS; Silveira JR; Morrey JD
    Acc Chem Res; 2006 Sep; 39(9):646-53. PubMed ID: 16981681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation of genuine prion infectivity by serial PMCA.
    Weber P; Giese A; Piening N; Mitteregger G; Thomzig A; Beekes M; Kretzschmar HA
    Vet Microbiol; 2007 Aug; 123(4):346-57. PubMed ID: 17493773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Full-length prion protein aggregates to amyloid fibrils and spherical particles by distinct pathways.
    El Moustaine D; Perrier V; Smeller L; Lange R; Torrent J
    FEBS J; 2008 May; 275(9):2021-31. PubMed ID: 18355314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Towards cellular receptors for prions.
    Lee KS; Linden R; Prado MA; Brentani RR; Martins VR
    Rev Med Virol; 2003; 13(6):399-408. PubMed ID: 14625887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of PrP in extraneural tissues.
    Brown KL; Ritchie DL; McBride PA; Bruce ME
    Microsc Res Tech; 2000 Jul; 50(1):40-5. PubMed ID: 10871547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro conversion of full-length mammalian prion protein produces amyloid form with physical properties of PrP(Sc).
    Bocharova OV; Breydo L; Parfenov AS; Salnikov VV; Baskakov IV
    J Mol Biol; 2005 Feb; 346(2):645-59. PubMed ID: 15670611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cellular prion protein co-localizes with nAChR beta4 subunit in brain and gastrointestinal tract.
    Petrakis S; Irinopoulou T; Panagiotidis CH; Engelstein R; Lindstrom J; Orr-Urtreger A; Gabizon R; Grigoriadis N; Sklaviadis T
    Eur J Neurosci; 2008 Feb; 27(3):612-20. PubMed ID: 18279314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prion protein has DNA strand transfer properties similar to retroviral nucleocapsid protein.
    Gabus C; Auxilien S; Péchoux C; Dormont D; Swietnicki W; Morillas M; Surewicz W; Nandi P; Darlix JL
    J Mol Biol; 2001 Apr; 307(4):1011-21. PubMed ID: 11286552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amyloid formation by recombinant full-length prion proteins in phospholipid bicelle solutions.
    Lührs T; Zahn R; Wüthrich K
    J Mol Biol; 2006 Mar; 357(3):833-41. PubMed ID: 16466741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ultrastructural localization of prion proteins: physiological and pathological implications.
    Fournier JG; Escaig-Haye F; Grigoriev V
    Microsc Res Tech; 2000 Jul; 50(1):76-88. PubMed ID: 10871551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prion agent diversity and species barrier.
    Béringue V; Vilotte JL; Laude H
    Vet Res; 2008; 39(4):47. PubMed ID: 18519020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural insights into the interaction between prion protein and nucleic acid.
    Lima LM; Cordeiro Y; Tinoco LW; Marques AF; Oliveira CL; Sampath S; Kodali R; Choi G; Foguel D; Torriani I; Caughey B; Silva JL
    Biochemistry; 2006 Aug; 45(30):9180-7. PubMed ID: 16866364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural insights into alternate aggregated prion protein forms.
    Polano M; Bek A; Benetti F; Lazzarino M; Legname G
    J Mol Biol; 2009 Nov; 393(5):1033-42. PubMed ID: 19720066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prion strain discrimination using luminescent conjugated polymers.
    Sigurdson CJ; Nilsson KP; Hornemann S; Manco G; Polymenidou M; Schwarz P; Leclerc M; Hammarström P; Wüthrich K; Aguzzi A
    Nat Methods; 2007 Dec; 4(12):1023-30. PubMed ID: 18026110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibril conformation as the basis of species- and strain-dependent seeding specificity of mammalian prion amyloids.
    Jones EM; Surewicz WK
    Cell; 2005 Apr; 121(1):63-72. PubMed ID: 15820679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.